NCT06037031View on ClinicalTrials.gov

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

July 3, 2024

Study Completion Date

July 3, 2024

Conditions
Renal Impairment
Interventions
DRUG

Drug: PF-07923568

A single dose of PF-07923568 administered orally as 4 capsules

Trial Locations (6)

32809

Orlando Clinical Research Center, Orlando

33603

Genesis Clinical Research, LLC, Tampa

55114

Prism Research LLC dba Nucleus Network, Saint Paul

78212

Clinical Trials of Texas, LLC, San Antonio

78229

Clinical Trials of Texas, LLC dba Flourish Research, San Antonio

Clinical Trials of Texas, LLC, San Antonio

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function | Biotech Hunter | Biotech Hunter